- Advanced ovarian cancer: what should be the standard of care?
-
Goff BA
- KMID: 2288564
- J Gynecol Oncol.
- 2013 Jan;24(1):83-91.
- doi: 10.3802/jgo.2013.24.1.83
The standard treatment of advanced ovarian cancer is rapidly changing. As we begin to understand that epithelial ovarian cancer is a heterogeneous disease, our treatment strategies are evolving to include... -
- CITED
-
- Close
- SHARE
-
- Close
- Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
-
Martin JY, Urban RR, Liao JB, Goff BA
- KMID: 2374249
- J Gynecol Oncol.
- 2016 Sep;27(5):e47.
- doi: 10.3802/jgo.2016.27.e47
OBJECTIVE: Bevacizumab was recently approved by the US Food and Drug Administration for use in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers
-
Vogel TJ, Knickerbocker A, Shah CA, Schiff MA, Isacson C, Garcia RL, Goff BA
- KMID: 2158799
- J Gynecol Oncol.
- 2015 Jan;26(1):25-31.
- doi: 10.3802/jgo.2015.26.1.25
OBJECTIVE: Despite the rarity of uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCCC), they contribute disproportionately to endometrial cancer deaths. Sufficient clinical information regarding treatment and prognosis... -
- CITED
-
- Close
- SHARE
-
- Close
